BNET Industries
Schering-Plough Corp. (SGP) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $12.6B
- Profit
- Dec 31 2007
- ($1.4B)
- Market Cap
- Jul 02 2008
- $31.5B
Latest News and Analysis
FDA Stings Pharma, Big and Small
Michael Steinberg submits: The first shock came after Merck MRK and Schering-Plough’s SGP Vytorin ENHANCE study. Surrogate markers like cholesterol counts would no longer be enough to garner marketing approval. Genzyme GENZ and Isis ISIS received the first blow. Isis’ cholesterol drug Mipomersen would have to undergo an outcomes study...
Investing in Summer FUN-damentals: Nike, Urban Outfitters, Schering-Plough, Cedar Fair
Zacks.com submits: The first day of summer arrives on June 20, 2008 this year. One way to put some fun into your summer is to invest in fundamentally sound companies that earn profits while you work on a tan. Therefore, I decided to take a look at...
Schering-Plough Now in the Feds' Crosshairs
The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries. Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its ...
Fred Hassan, Schering's $30 Million Man
Schering-Plough has had a fairly miserable year so far, thanks to its apparent efforts to keep bad scientific news about the cholesterol pill Vytorin out of the public eye. CEO Fred Hassan, however, is still living off last year's glory -- even if it might well have been far less...
Schering-Plough Corp. Q1 2008 Earnings Call Transcript
Schering-Plough Corp. Q1 2008 Earnings Call Transcript
Schering-Plough Corp. Q4 2007 Earnings Call Transcript
Schering-Plough Corp. Q4 2007 Earnings Call Transcript
Schering-Plough Q3 2007 Earnings Call Transcript
Schering-Plough Q3 2007 Earnings Call Transcript
Schering-Plough Corp. Q2 2007 Earnings Call Transcript
Schering-Plough Corp. Q2 2007 Earnings Call Transcript
Millennium and Schering-Plough Initiate Clinical Trial With INTEGRILIN (Eptifibatide) Injection in Early Use Acute Coronary Syndrome Setting
In this article Millennium Pharmaceuticals, Inc. and Schering-Plough Corporation discusses the initiation of a multicenter phase IIIb clinical trial to evaluate the benefit of INTEGRILIN when administered early to high-risk patients experiencing non-ST-segment elevation acute coronary syndrome. The trial, known as EARLY ACS (Early Glycoprotein IIb-IIIa Inhibition in Non-ST-segment Elevation...
Additional Resources
Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
KENILWORTH, N.J., June 24 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Aug. 26, 2008, to shareholders of record at the close of business on Aug. 1, 2008. As...
VIVALIS GRANTS RIGHTS TO EBx(R) CELL LINE FOR TESTING IN PRODUCTION OF VIRAL VACCINES
- VIVALIS announced today that ithas signed a research license with an animal health companyundisclosed, to evaluate EBx® cell line (EB66) for theproduction of several viral vaccines. The world-wide veterinary vaccine market was 1.5 billion USD in2007. VIVALIS has already licensed its EBx® platform to majoractors in the field including:...
Research and Markets: A SWOT Framework Analysis of Schering-Plough Corporation Completes This In-Depth Company Analysis
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/cb9f8f/analysis_of_scheri) has announced the addition of the "Analysis of Schering-Plough Corporation" companyprofile to their offering. We present Analysis of Schering-Plough Corporation. A complete and comprehensive analysis of Schering-Plough Corporation, includes an overview of the industry the company operates in, a PEST Framework...
Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
KENILWORTH, N.J., June 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation is scheduled to announce its sales and earnings results for the 2008 second quarter on Monday, July 21, 2008. At 8 a.m. EDT on that day, Schering-Plough will conduct a conference call to review results for the 2008...
Golimumab and Actemra Will Be Two of the Most Successful Emerging Novel Agents in the Rheumatoid Arthritis Drug Treatment Market
Among Currently Available Therapies, Enbrel and Humira Will Continue to Dominate the Market Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that...
IDA Ireland to Exhibit at BIO International Convention at Booth #3147
Press kit materials are available online at http://virtualpressoffice.com/kit/IDAIreland DUBLIN, Ireland -- The life sciences sector in Ireland continues to thrive, both with indigenous and overseas companies. Ireland is now in a leadership position in many key business segments. In bio-pharmaceuticals, Eli Lilly joined Schering Plough, Wyeth, Genzyme and...
Zacks Analyst Blog Highlights: Metabasis Therapeutics Inc., Schering-Plough, ASM International, Applied Materials Inc. and Beacon Roofing Supply, Inc
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Metabasis Therapeutics Inc. (Nasdaq: MBRX), Schering-Plough (NYSE: SGP), ASM International (Nasdaq:...
ASU plans huge rooftop solar-power plant
More than 20 percent of the energy needs of Arizona State University's main campus eventually could be met by one of the largest rooftop solar-power plants in the U.S. The university announced an agreement Tuesday under which three companies would install, at their expense, solar electricity- generating...
Schering-Plough Announces Fruit of the Earth to Change Sun Care Packaging After Court Hearing
DALLAS, June 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that the Federal District Court for the Northern District of Texas Dallas Division has confirmed that Fruit of the Earth must promptly change the packaging of its generic, no-name sport and baby sunscreens. Schering-Plough maintains that the Fruit of the...
A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market
Ustekinumab Will Earn a 5.4 Percent Patient Share by 2012, According to a New Report from Decision Resources WALTHAM, Mass., June 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that induces...
Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
Lawsuit claims manufacturers misled consumers about the use of Zetia and Vytorin. SEATTLE, June 10 /PRNewswire/ -- Last week the U.S. District Court in New Jersey appointed Hagens Berman, along with four other firms, co-counsel in a case against Schering-Plough and Merck which claims the...
- Next »
- page 1 of 149
- « Previous
Sort byClose
- Incorporated: 1970
- CEO: Mr. Fred Hassan
Schering-Plough is a science-centered health care company operating through three business segments. Co.'s Human Prescription Pharmaceuticals segment discovers, develops, manufactures and markets human pharmaceutical products. Co.'s Consumer Health Care segment develops, manufactures and markets over-the-counter, foot care and sun care products. Co.'s Animal Health segment discovers, develops, manufactures and markets animal health products including vaccines. As of Dec 31 2007, Co. had subsidiaries in more than 55 countries outside the U.S. In addition, as of Dec 31 2007, Co. had business operations in more than 140 countries.
Key Competitors
Schering-Plough Corp. Company Info
Board of Directors
Mr. Fred Hassan
Chairman
Dr. Craig B. Thompson
Ms. Kathryn C. Turner
Mr. Robert F. W. van Oordt
Mr. Arthur F. Weinbach
Mr. Hans W. Becherer
Mr. Thomas J. Colligan
Mr. C. Robert Kidder
Mr. Eugene R. McGrath
General Carl E. Mundy Jr.
Mr. Antonio M. Perez
Ms. Patricia F. Russo
Mr. Jack L. Stahl
Contact Information
2000 Galloping Hill Road
Kenilworth, NJ
http://www.schering-plough.com
908 298-4000
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
